Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies.
Future Microbiol
; 16: 543-555, 2021 05.
Article
en En
| MEDLINE
| ID: mdl-33960817
Lay abstract Infections are a common cause of severe disease and death in older patients. Antibiotic treatment may also be complicated by age-related changes within the body. The present study analyzed results from three large clinical trials that assessed the benefits of the novel antibiotic ceftobiprole in the older population. In patients aged over 65 years with skin infections or with pneumonia acquired either in the community or in a hospital setting, ceftobiprole offered similar benefits to established antibiotics. There was also some preliminary evidence that older patients may respond more quickly to ceftobiprole compared with the other antibiotics used in these studies. Overall, ceftobiprole was well tolerated and will be a useful treatment option for infections in older patients. Clinical trial registration: NCT03137173, NCT00326287, NCT00210964, NCT00229008 (Clinicaltrials.gov).
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Cefalosporinas
/
Antibacterianos
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Future Microbiol
Asunto de la revista:
MICROBIOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Alemania